Effects of enzyme inducers efavirenz and tipranavir/ritonavir on the pharmacokinetics of the HIV integrase inhibitor dolutegravir View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2014-10

AUTHORS

Ivy Song, Julie Borland, Shuguang Chen, Phyllis Guta, Yu Lou, David Wilfret, Toshihiro Wajima, Paul Savina, Amanda Peppercorn, Stephen Castellino, David Wagner, Louise Hosking, Michael Mosteller, Justin P. Rubio, Stephen C. Piscitelli

ABSTRACT

PURPOSE: Dolutegravir (DTG) is an unboosted, integrase inhibitor for the treatment of HIV infection. Two studies evaluated the effects of efavirenz (EFV) and tipranavir/ritonavir (TPV/r) on DTG pharmacokinetics (PK) in healthy subjects. METHODS: The first study was an open-label crossover where 12 subjects received DTG 50 mg every 24 hours (q24h) for 5 days, followed by DTG 50 mg and EFV 600 mg q24h for 14 days. The second study was an open-label crossover where 18 subjects received DTG 50 mg q24h for 5 days followed by TPV/r 500/200 mg every 12 hours (q12h) for 7 days and then DTG 50 mg q24h and TPV/r 500/200 mg q12h for a further 5 days. Safety assessments and serial PK samples were collected. Non-compartmental PK analysis and geometric mean ratios and 90% confidence intervals were generated. RESULTS: The combination of DTG with EFV or TPV/r was generally well tolerated. Four subjects discontinued the TPV/r study due to increases in alanine aminotransferase that were considered related to TPV/r. Co-administration with EFV resulted in decreases of 57, 39 and 75% in DTG AUC(0-τ), Cmax and Cτ, respectively. Co-administration with TPV/r resulted in decreases of 59, 46 and 76% in DTG AUC(0-τ), Cmax and Cτ, respectively. CONCLUSIONS: Given the reductions in exposure and PK/pharmacodynamic relationships in phase II/III trials, DTG should be given at an increased dose of 50 mg twice daily when co-administered with EFV or TPV/r, and alternative regimens without inducers should be considered in integrase inhibitor-resistant patients. More... »

PAGES

1173-1179

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00228-014-1732-8

DOI

http://dx.doi.org/10.1007/s00228-014-1732-8

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1043400137

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/25146692


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Anti-HIV Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Area Under Curve", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Benzoxazines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cross-Over Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Combinations", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Interactions", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "HIV Integrase Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Heterocyclic Compounds, 3-Ring", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Models, Biological", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pyridines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pyrones", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Ritonavir", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Young Adult", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "name": [
            "GlaxoSmithKline, 5 Moore Drive, Research Triangle Park, 27709, Durham, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Song", 
        "givenName": "Ivy", 
        "id": "sg:person.0741434051.90", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0741434051.90"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "GlaxoSmithKline, 5 Moore Drive, Research Triangle Park, 27709, Durham, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Borland", 
        "givenName": "Julie", 
        "id": "sg:person.0575606363.86", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0575606363.86"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "GlaxoSmithKline, 5 Moore Drive, Research Triangle Park, 27709, Durham, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chen", 
        "givenName": "Shuguang", 
        "id": "sg:person.01272345137.07", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01272345137.07"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "GlaxoSmithKline (United Kingdom)", 
          "id": "https://www.grid.ac/institutes/grid.418236.a", 
          "name": [
            "GlaxoSmithKline, Stockley Park, Uxbridge, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Guta", 
        "givenName": "Phyllis", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "GlaxoSmithKline, 5 Moore Drive, Research Triangle Park, 27709, Durham, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lou", 
        "givenName": "Yu", 
        "id": "sg:person.01075710535.47", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01075710535.47"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "GlaxoSmithKline, 5 Moore Drive, Research Triangle Park, 27709, Durham, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wilfret", 
        "givenName": "David", 
        "id": "sg:person.07374132774.32", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07374132774.32"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Shionogi (Japan)", 
          "id": "https://www.grid.ac/institutes/grid.419164.f", 
          "name": [
            "Shionogi & Co., Ltd., Osaka, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wajima", 
        "givenName": "Toshihiro", 
        "id": "sg:person.01364605124.29", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01364605124.29"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "GlaxoSmithKline, 5 Moore Drive, Research Triangle Park, 27709, Durham, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Savina", 
        "givenName": "Paul", 
        "id": "sg:person.0731212511.71", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0731212511.71"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "GlaxoSmithKline, 5 Moore Drive, Research Triangle Park, 27709, Durham, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Peppercorn", 
        "givenName": "Amanda", 
        "id": "sg:person.01316471724.72", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01316471724.72"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "GlaxoSmithKline, 5 Moore Drive, Research Triangle Park, 27709, Durham, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Castellino", 
        "givenName": "Stephen", 
        "id": "sg:person.01002361140.23", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01002361140.23"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "GlaxoSmithKline, 5 Moore Drive, Research Triangle Park, 27709, Durham, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wagner", 
        "givenName": "David", 
        "id": "sg:person.01317322142.96", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01317322142.96"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "GlaxoSmithKline (United Kingdom)", 
          "id": "https://www.grid.ac/institutes/grid.418236.a", 
          "name": [
            "GlaxoSmithKline, Stevenage, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hosking", 
        "givenName": "Louise", 
        "id": "sg:person.01137555054.70", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01137555054.70"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "GlaxoSmithKline, 5 Moore Drive, Research Triangle Park, 27709, Durham, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mosteller", 
        "givenName": "Michael", 
        "id": "sg:person.01234343615.46", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01234343615.46"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "GlaxoSmithKline (United Kingdom)", 
          "id": "https://www.grid.ac/institutes/grid.418236.a", 
          "name": [
            "GlaxoSmithKline, Stevenage, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Rubio", 
        "givenName": "Justin P.", 
        "id": "sg:person.011235763662.85", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011235763662.85"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "GlaxoSmithKline, 5 Moore Drive, Research Triangle Park, 27709, Durham, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Piscitelli", 
        "givenName": "Stephen C.", 
        "id": "sg:person.01100274674.19", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01100274674.19"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1128/aac.05739-11", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006959899"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1473-3099(11)70290-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012328949"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1128/aac.00842-09", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012666122"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/qai.0b013e318276cda9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013562829"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/qai.0b013e318276cda9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013562829"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/qai.0b013e318276cda9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013562829"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1021/js970486q", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014403362"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/0091270010371113", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017710989"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.antiviral.2009.09.001", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022449206"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(13)61221-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022615950"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1128/aac.00073-11", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025297073"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1365-2125.2011.03947.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028679510"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/qai.0b013e318183a982", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030792638"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/qai.0b013e318183a982", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030792638"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1124/dmd.112.048918", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045191601"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(12)61853-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045841940"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1128/aac.00292-13", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046871169"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00003088-200140120-00002", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048700706", 
          "https://doi.org/10.2165/00003088-200140120-00002"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00003088-200140120-00002", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048700706", 
          "https://doi.org/10.2165/00003088-200140120-00002"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.7448/ias.15.6.18112", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049897586"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1128/aac.01486-08", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050895815"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1310/rrx7-49me-27v7-mwwv", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064986057"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1310/rrx7-49me-27v7-mwwv", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064986057"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2014-10", 
    "datePublishedReg": "2014-10-01", 
    "description": "PURPOSE: Dolutegravir (DTG) is an unboosted, integrase inhibitor for the treatment of HIV infection. Two studies evaluated the effects of efavirenz (EFV) and tipranavir/ritonavir (TPV/r) on DTG pharmacokinetics (PK) in healthy subjects.\nMETHODS: The first study was an open-label crossover where 12 subjects received DTG 50 mg every 24 hours (q24h) for 5 days, followed by DTG 50 mg and EFV 600 mg q24h for 14 days. The second study was an open-label crossover where 18 subjects received DTG 50 mg q24h for 5 days followed by TPV/r 500/200 mg every 12 hours (q12h) for 7 days and then DTG 50 mg q24h and TPV/r 500/200 mg q12h for a further 5 days. Safety assessments and serial PK samples were collected. Non-compartmental PK analysis and geometric mean ratios and 90% confidence intervals were generated.\nRESULTS: The combination of DTG with EFV or TPV/r was generally well tolerated. Four subjects discontinued the TPV/r study due to increases in alanine aminotransferase that were considered related to TPV/r. Co-administration with EFV resulted in decreases of 57, 39 and 75% in DTG AUC(0-\u03c4), Cmax and C\u03c4, respectively. Co-administration with TPV/r resulted in decreases of 59, 46 and 76% in DTG AUC(0-\u03c4), Cmax and C\u03c4, respectively.\nCONCLUSIONS: Given the reductions in exposure and PK/pharmacodynamic relationships in phase II/III trials, DTG should be given at an increased dose of 50 mg twice daily when co-administered with EFV or TPV/r, and alternative regimens without inducers should be considered in integrase inhibitor-resistant patients.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s00228-014-1732-8", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1054337", 
        "issn": [
          "0031-6970", 
          "1432-1041"
        ], 
        "name": "European Journal of Clinical Pharmacology", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "10", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "70"
      }
    ], 
    "name": "Effects of enzyme inducers efavirenz and tipranavir/ritonavir on the pharmacokinetics of the HIV integrase inhibitor dolutegravir", 
    "pagination": "1173-1179", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "cebb2057897e46861b5d520c8c6df7cad23cc8a3d453de92848f861b6ca83936"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "25146692"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "1256165"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00228-014-1732-8"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1043400137"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00228-014-1732-8", 
      "https://app.dimensions.ai/details/publication/pub.1043400137"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T10:01", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000347_0000000347/records_89819_00000001.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007/s00228-014-1732-8"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00228-014-1732-8'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00228-014-1732-8'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00228-014-1732-8'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00228-014-1732-8'


 

This table displays all metadata directly associated to this object as RDF triples.

323 TRIPLES      21 PREDICATES      66 URIs      40 LITERALS      28 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00228-014-1732-8 schema:about N023554eebee24351a890c90c8c42fbcc
2 N04ff159705ae43caa55b56967f6a506b
3 N0bc81fbe7b174944b68e358b58018881
4 N178d59072a86401eba3cf1774006b7be
5 N2d79490bbd8744999efd244373836b3b
6 N373aafc52c5d47f58e2fe3f489f400a5
7 N38ab4d8b5a3d480bbd543bd14e3cd590
8 N421594b9c81842dd8f10babb358b4527
9 N4415c4cb05814c14a89279ace3932d88
10 N93ec6051791646758852f6b54b6db32a
11 N9fa4610d63584ebbafd73a4b75655beb
12 Nac0c0a2145944961a67e6e7dc9a19bc2
13 Nc124fb30ac66414893fef380ec05ce80
14 Nc4e8398842b14d47b84c4e198ab9939f
15 Nc686c4bf2a9145a0906c016a238ca53d
16 Ncd299e8d37de49cbbba4328aecb0eef9
17 Nd28f0be070e848b699701fa55483b6c1
18 Ne3b3ee4551e943c4b89e447c31735519
19 Nf7a4026c993044489ec6915d65b93265
20 anzsrc-for:11
21 anzsrc-for:1103
22 schema:author N754be0e9007749f187558fe89e9f83ae
23 schema:citation sg:pub.10.2165/00003088-200140120-00002
24 https://doi.org/10.1016/j.antiviral.2009.09.001
25 https://doi.org/10.1016/s0140-6736(12)61853-4
26 https://doi.org/10.1016/s0140-6736(13)61221-0
27 https://doi.org/10.1016/s1473-3099(11)70290-0
28 https://doi.org/10.1021/js970486q
29 https://doi.org/10.1097/qai.0b013e318183a982
30 https://doi.org/10.1097/qai.0b013e318276cda9
31 https://doi.org/10.1111/j.1365-2125.2011.03947.x
32 https://doi.org/10.1124/dmd.112.048918
33 https://doi.org/10.1128/aac.00073-11
34 https://doi.org/10.1128/aac.00292-13
35 https://doi.org/10.1128/aac.00842-09
36 https://doi.org/10.1128/aac.01486-08
37 https://doi.org/10.1128/aac.05739-11
38 https://doi.org/10.1177/0091270010371113
39 https://doi.org/10.1310/rrx7-49me-27v7-mwwv
40 https://doi.org/10.7448/ias.15.6.18112
41 schema:datePublished 2014-10
42 schema:datePublishedReg 2014-10-01
43 schema:description PURPOSE: Dolutegravir (DTG) is an unboosted, integrase inhibitor for the treatment of HIV infection. Two studies evaluated the effects of efavirenz (EFV) and tipranavir/ritonavir (TPV/r) on DTG pharmacokinetics (PK) in healthy subjects. METHODS: The first study was an open-label crossover where 12 subjects received DTG 50 mg every 24 hours (q24h) for 5 days, followed by DTG 50 mg and EFV 600 mg q24h for 14 days. The second study was an open-label crossover where 18 subjects received DTG 50 mg q24h for 5 days followed by TPV/r 500/200 mg every 12 hours (q12h) for 7 days and then DTG 50 mg q24h and TPV/r 500/200 mg q12h for a further 5 days. Safety assessments and serial PK samples were collected. Non-compartmental PK analysis and geometric mean ratios and 90% confidence intervals were generated. RESULTS: The combination of DTG with EFV or TPV/r was generally well tolerated. Four subjects discontinued the TPV/r study due to increases in alanine aminotransferase that were considered related to TPV/r. Co-administration with EFV resulted in decreases of 57, 39 and 75% in DTG AUC(0-τ), Cmax and Cτ, respectively. Co-administration with TPV/r resulted in decreases of 59, 46 and 76% in DTG AUC(0-τ), Cmax and Cτ, respectively. CONCLUSIONS: Given the reductions in exposure and PK/pharmacodynamic relationships in phase II/III trials, DTG should be given at an increased dose of 50 mg twice daily when co-administered with EFV or TPV/r, and alternative regimens without inducers should be considered in integrase inhibitor-resistant patients.
44 schema:genre research_article
45 schema:inLanguage en
46 schema:isAccessibleForFree true
47 schema:isPartOf N322c7e0148cc4158a85ac7fee9931f02
48 Nd7746a71e8e9480686960059f53f31de
49 sg:journal.1054337
50 schema:name Effects of enzyme inducers efavirenz and tipranavir/ritonavir on the pharmacokinetics of the HIV integrase inhibitor dolutegravir
51 schema:pagination 1173-1179
52 schema:productId N1fbd84317e4a447ebdc2464570737916
53 N9dabd05fe24f4418960098ec08f1e6db
54 Na4a37465a4644db1bdc3329148bb741a
55 Nbf556f51d0424918ae217d6e8a5c427a
56 Ncf85198ac14f49228d493306af64c842
57 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043400137
58 https://doi.org/10.1007/s00228-014-1732-8
59 schema:sdDatePublished 2019-04-11T10:01
60 schema:sdLicense https://scigraph.springernature.com/explorer/license/
61 schema:sdPublisher Nff91d85b182e4fa590a5129736f09a00
62 schema:url http://link.springer.com/10.1007/s00228-014-1732-8
63 sgo:license sg:explorer/license/
64 sgo:sdDataset articles
65 rdf:type schema:ScholarlyArticle
66 N023554eebee24351a890c90c8c42fbcc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
67 schema:name Humans
68 rdf:type schema:DefinedTerm
69 N04ff159705ae43caa55b56967f6a506b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
70 schema:name Anti-HIV Agents
71 rdf:type schema:DefinedTerm
72 N0582fe1a0c0547189187aec80f2bdd40 schema:name GlaxoSmithKline, 5 Moore Drive, Research Triangle Park, 27709, Durham, NC, USA
73 rdf:type schema:Organization
74 N0bc81fbe7b174944b68e358b58018881 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
75 schema:name Drug Combinations
76 rdf:type schema:DefinedTerm
77 N178d59072a86401eba3cf1774006b7be schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
78 schema:name Male
79 rdf:type schema:DefinedTerm
80 N1a190cbf3770408da6ca876da0d2f3b0 rdf:first sg:person.01364605124.29
81 rdf:rest N43bc473dc5034d1f81a99c18af9567f0
82 N1fbd84317e4a447ebdc2464570737916 schema:name dimensions_id
83 schema:value pub.1043400137
84 rdf:type schema:PropertyValue
85 N2466abe6e76c4d5598b3675d64484cd4 rdf:first sg:person.07374132774.32
86 rdf:rest N1a190cbf3770408da6ca876da0d2f3b0
87 N25ec91583ea0480fba54aedc960bbd4a schema:name GlaxoSmithKline, 5 Moore Drive, Research Triangle Park, 27709, Durham, NC, USA
88 rdf:type schema:Organization
89 N2d79490bbd8744999efd244373836b3b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
90 schema:name Drug Interactions
91 rdf:type schema:DefinedTerm
92 N322c7e0148cc4158a85ac7fee9931f02 schema:issueNumber 10
93 rdf:type schema:PublicationIssue
94 N373aafc52c5d47f58e2fe3f489f400a5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
95 schema:name Pyridines
96 rdf:type schema:DefinedTerm
97 N38ab4d8b5a3d480bbd543bd14e3cd590 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
98 schema:name Models, Biological
99 rdf:type schema:DefinedTerm
100 N3c05955ddfa04c0a954facc47d39607f rdf:first sg:person.01100274674.19
101 rdf:rest rdf:nil
102 N4212b81c57244513a5de4d6bf1cfee55 rdf:first sg:person.0575606363.86
103 rdf:rest N4d621fcc91674ffab656aa2a044213bd
104 N421594b9c81842dd8f10babb358b4527 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
105 schema:name Female
106 rdf:type schema:DefinedTerm
107 N43bc473dc5034d1f81a99c18af9567f0 rdf:first sg:person.0731212511.71
108 rdf:rest N7ef6c545e4b2426cb880074e3cd53a6a
109 N4415c4cb05814c14a89279ace3932d88 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
110 schema:name Ritonavir
111 rdf:type schema:DefinedTerm
112 N48086bff34e24fa7ac116f852b95428b rdf:first sg:person.01075710535.47
113 rdf:rest N2466abe6e76c4d5598b3675d64484cd4
114 N4d621fcc91674ffab656aa2a044213bd rdf:first sg:person.01272345137.07
115 rdf:rest Nced3567b46674361b7b206ca89ba467c
116 N5128add9840e45f78a2236da8bae8bda schema:name GlaxoSmithKline, 5 Moore Drive, Research Triangle Park, 27709, Durham, NC, USA
117 rdf:type schema:Organization
118 N5beb5848a0d442789f5af4c118a93dea schema:name GlaxoSmithKline, 5 Moore Drive, Research Triangle Park, 27709, Durham, NC, USA
119 rdf:type schema:Organization
120 N5d50e9c973ba4b07b55915ad27c1f81a schema:name GlaxoSmithKline, 5 Moore Drive, Research Triangle Park, 27709, Durham, NC, USA
121 rdf:type schema:Organization
122 N754be0e9007749f187558fe89e9f83ae rdf:first sg:person.0741434051.90
123 rdf:rest N4212b81c57244513a5de4d6bf1cfee55
124 N7ef6c545e4b2426cb880074e3cd53a6a rdf:first sg:person.01316471724.72
125 rdf:rest N8fb08f67a5994f68b309675bdd432ebc
126 N8fb08f67a5994f68b309675bdd432ebc rdf:first sg:person.01002361140.23
127 rdf:rest Na5523b12e7bf4858ac77bccc63832ec9
128 N901b078cf2264baab99d6bf3e06183c1 schema:name GlaxoSmithKline, 5 Moore Drive, Research Triangle Park, 27709, Durham, NC, USA
129 rdf:type schema:Organization
130 N93ec6051791646758852f6b54b6db32a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Adult
132 rdf:type schema:DefinedTerm
133 N9dabd05fe24f4418960098ec08f1e6db schema:name pubmed_id
134 schema:value 25146692
135 rdf:type schema:PropertyValue
136 N9de8bf8fc5a94ee8b3352c55457d04af schema:affiliation https://www.grid.ac/institutes/grid.418236.a
137 schema:familyName Guta
138 schema:givenName Phyllis
139 rdf:type schema:Person
140 N9f41e9cd9eef42a193e8df8a4b211ffc schema:name GlaxoSmithKline, 5 Moore Drive, Research Triangle Park, 27709, Durham, NC, USA
141 rdf:type schema:Organization
142 N9fa4610d63584ebbafd73a4b75655beb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
143 schema:name Benzoxazines
144 rdf:type schema:DefinedTerm
145 N9fb95ad3679f4a78bdb8bc05a1d6571a schema:name GlaxoSmithKline, 5 Moore Drive, Research Triangle Park, 27709, Durham, NC, USA
146 rdf:type schema:Organization
147 Na4a37465a4644db1bdc3329148bb741a schema:name nlm_unique_id
148 schema:value 1256165
149 rdf:type schema:PropertyValue
150 Na5523b12e7bf4858ac77bccc63832ec9 rdf:first sg:person.01317322142.96
151 rdf:rest Nb08f01eb15f74975b89fbdf18370206d
152 Na804ec01eb0d49ea8f57203f440b5c98 schema:name GlaxoSmithKline, 5 Moore Drive, Research Triangle Park, 27709, Durham, NC, USA
153 rdf:type schema:Organization
154 Na8ce1ae871224953863c4bb0a8a2d64f rdf:first sg:person.011235763662.85
155 rdf:rest N3c05955ddfa04c0a954facc47d39607f
156 Nac0c0a2145944961a67e6e7dc9a19bc2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
157 schema:name Young Adult
158 rdf:type schema:DefinedTerm
159 Nb08f01eb15f74975b89fbdf18370206d rdf:first sg:person.01137555054.70
160 rdf:rest Nc5f81aa0fb9b4e9d83bf1548ad6543ad
161 Nbc4ec3b263794bbb9d37ec6fe7c5d18d schema:name GlaxoSmithKline, 5 Moore Drive, Research Triangle Park, 27709, Durham, NC, USA
162 rdf:type schema:Organization
163 Nbf556f51d0424918ae217d6e8a5c427a schema:name doi
164 schema:value 10.1007/s00228-014-1732-8
165 rdf:type schema:PropertyValue
166 Nc124fb30ac66414893fef380ec05ce80 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
167 schema:name Heterocyclic Compounds, 3-Ring
168 rdf:type schema:DefinedTerm
169 Nc4e8398842b14d47b84c4e198ab9939f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
170 schema:name Aged
171 rdf:type schema:DefinedTerm
172 Nc5f81aa0fb9b4e9d83bf1548ad6543ad rdf:first sg:person.01234343615.46
173 rdf:rest Na8ce1ae871224953863c4bb0a8a2d64f
174 Nc686c4bf2a9145a0906c016a238ca53d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
175 schema:name Pyrones
176 rdf:type schema:DefinedTerm
177 Ncc4fee149ef94a19893112dffd53c83f schema:name GlaxoSmithKline, 5 Moore Drive, Research Triangle Park, 27709, Durham, NC, USA
178 rdf:type schema:Organization
179 Ncd299e8d37de49cbbba4328aecb0eef9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
180 schema:name HIV Integrase Inhibitors
181 rdf:type schema:DefinedTerm
182 Nced3567b46674361b7b206ca89ba467c rdf:first N9de8bf8fc5a94ee8b3352c55457d04af
183 rdf:rest N48086bff34e24fa7ac116f852b95428b
184 Ncf85198ac14f49228d493306af64c842 schema:name readcube_id
185 schema:value cebb2057897e46861b5d520c8c6df7cad23cc8a3d453de92848f861b6ca83936
186 rdf:type schema:PropertyValue
187 Nd28f0be070e848b699701fa55483b6c1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
188 schema:name Cross-Over Studies
189 rdf:type schema:DefinedTerm
190 Nd7746a71e8e9480686960059f53f31de schema:volumeNumber 70
191 rdf:type schema:PublicationVolume
192 Ne3b3ee4551e943c4b89e447c31735519 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
193 schema:name Middle Aged
194 rdf:type schema:DefinedTerm
195 Nf7a4026c993044489ec6915d65b93265 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
196 schema:name Area Under Curve
197 rdf:type schema:DefinedTerm
198 Nff91d85b182e4fa590a5129736f09a00 schema:name Springer Nature - SN SciGraph project
199 rdf:type schema:Organization
200 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
201 schema:name Medical and Health Sciences
202 rdf:type schema:DefinedTerm
203 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
204 schema:name Clinical Sciences
205 rdf:type schema:DefinedTerm
206 sg:journal.1054337 schema:issn 0031-6970
207 1432-1041
208 schema:name European Journal of Clinical Pharmacology
209 rdf:type schema:Periodical
210 sg:person.01002361140.23 schema:affiliation N9fb95ad3679f4a78bdb8bc05a1d6571a
211 schema:familyName Castellino
212 schema:givenName Stephen
213 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01002361140.23
214 rdf:type schema:Person
215 sg:person.01075710535.47 schema:affiliation N9f41e9cd9eef42a193e8df8a4b211ffc
216 schema:familyName Lou
217 schema:givenName Yu
218 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01075710535.47
219 rdf:type schema:Person
220 sg:person.01100274674.19 schema:affiliation N25ec91583ea0480fba54aedc960bbd4a
221 schema:familyName Piscitelli
222 schema:givenName Stephen C.
223 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01100274674.19
224 rdf:type schema:Person
225 sg:person.011235763662.85 schema:affiliation https://www.grid.ac/institutes/grid.418236.a
226 schema:familyName Rubio
227 schema:givenName Justin P.
228 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011235763662.85
229 rdf:type schema:Person
230 sg:person.01137555054.70 schema:affiliation https://www.grid.ac/institutes/grid.418236.a
231 schema:familyName Hosking
232 schema:givenName Louise
233 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01137555054.70
234 rdf:type schema:Person
235 sg:person.01234343615.46 schema:affiliation N5beb5848a0d442789f5af4c118a93dea
236 schema:familyName Mosteller
237 schema:givenName Michael
238 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01234343615.46
239 rdf:type schema:Person
240 sg:person.01272345137.07 schema:affiliation Ncc4fee149ef94a19893112dffd53c83f
241 schema:familyName Chen
242 schema:givenName Shuguang
243 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01272345137.07
244 rdf:type schema:Person
245 sg:person.01316471724.72 schema:affiliation N5128add9840e45f78a2236da8bae8bda
246 schema:familyName Peppercorn
247 schema:givenName Amanda
248 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01316471724.72
249 rdf:type schema:Person
250 sg:person.01317322142.96 schema:affiliation N901b078cf2264baab99d6bf3e06183c1
251 schema:familyName Wagner
252 schema:givenName David
253 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01317322142.96
254 rdf:type schema:Person
255 sg:person.01364605124.29 schema:affiliation https://www.grid.ac/institutes/grid.419164.f
256 schema:familyName Wajima
257 schema:givenName Toshihiro
258 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01364605124.29
259 rdf:type schema:Person
260 sg:person.0575606363.86 schema:affiliation Nbc4ec3b263794bbb9d37ec6fe7c5d18d
261 schema:familyName Borland
262 schema:givenName Julie
263 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0575606363.86
264 rdf:type schema:Person
265 sg:person.0731212511.71 schema:affiliation N0582fe1a0c0547189187aec80f2bdd40
266 schema:familyName Savina
267 schema:givenName Paul
268 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0731212511.71
269 rdf:type schema:Person
270 sg:person.07374132774.32 schema:affiliation Na804ec01eb0d49ea8f57203f440b5c98
271 schema:familyName Wilfret
272 schema:givenName David
273 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07374132774.32
274 rdf:type schema:Person
275 sg:person.0741434051.90 schema:affiliation N5d50e9c973ba4b07b55915ad27c1f81a
276 schema:familyName Song
277 schema:givenName Ivy
278 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0741434051.90
279 rdf:type schema:Person
280 sg:pub.10.2165/00003088-200140120-00002 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048700706
281 https://doi.org/10.2165/00003088-200140120-00002
282 rdf:type schema:CreativeWork
283 https://doi.org/10.1016/j.antiviral.2009.09.001 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022449206
284 rdf:type schema:CreativeWork
285 https://doi.org/10.1016/s0140-6736(12)61853-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045841940
286 rdf:type schema:CreativeWork
287 https://doi.org/10.1016/s0140-6736(13)61221-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022615950
288 rdf:type schema:CreativeWork
289 https://doi.org/10.1016/s1473-3099(11)70290-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012328949
290 rdf:type schema:CreativeWork
291 https://doi.org/10.1021/js970486q schema:sameAs https://app.dimensions.ai/details/publication/pub.1014403362
292 rdf:type schema:CreativeWork
293 https://doi.org/10.1097/qai.0b013e318183a982 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030792638
294 rdf:type schema:CreativeWork
295 https://doi.org/10.1097/qai.0b013e318276cda9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013562829
296 rdf:type schema:CreativeWork
297 https://doi.org/10.1111/j.1365-2125.2011.03947.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1028679510
298 rdf:type schema:CreativeWork
299 https://doi.org/10.1124/dmd.112.048918 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045191601
300 rdf:type schema:CreativeWork
301 https://doi.org/10.1128/aac.00073-11 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025297073
302 rdf:type schema:CreativeWork
303 https://doi.org/10.1128/aac.00292-13 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046871169
304 rdf:type schema:CreativeWork
305 https://doi.org/10.1128/aac.00842-09 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012666122
306 rdf:type schema:CreativeWork
307 https://doi.org/10.1128/aac.01486-08 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050895815
308 rdf:type schema:CreativeWork
309 https://doi.org/10.1128/aac.05739-11 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006959899
310 rdf:type schema:CreativeWork
311 https://doi.org/10.1177/0091270010371113 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017710989
312 rdf:type schema:CreativeWork
313 https://doi.org/10.1310/rrx7-49me-27v7-mwwv schema:sameAs https://app.dimensions.ai/details/publication/pub.1064986057
314 rdf:type schema:CreativeWork
315 https://doi.org/10.7448/ias.15.6.18112 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049897586
316 rdf:type schema:CreativeWork
317 https://www.grid.ac/institutes/grid.418236.a schema:alternateName GlaxoSmithKline (United Kingdom)
318 schema:name GlaxoSmithKline, Stevenage, UK
319 GlaxoSmithKline, Stockley Park, Uxbridge, UK
320 rdf:type schema:Organization
321 https://www.grid.ac/institutes/grid.419164.f schema:alternateName Shionogi (Japan)
322 schema:name Shionogi & Co., Ltd., Osaka, Japan
323 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...